LUC00284I2 - - Google Patents
Download PDFInfo
- Publication number
- LUC00284I2 LUC00284I2 LU00284C LUC00284C LUC00284I2 LU C00284 I2 LUC00284 I2 LU C00284I2 LU 00284 C LU00284 C LU 00284C LU C00284 C LUC00284 C LU C00284C LU C00284 I2 LUC00284 I2 LU C00284I2
- Authority
- LU
- Luxembourg
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361920547P | 2013-12-24 | 2013-12-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LUC00284I2 true LUC00284I2 (fr) | 2025-05-12 |
Family
ID=52347464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU00284C LUC00284I2 (fr) | 2013-12-24 | 2022-11-09 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10316073B2 (fr) |
| EP (2) | EP3087095B1 (fr) |
| JP (2) | JP6554473B2 (fr) |
| KR (3) | KR20220152546A (fr) |
| CN (2) | CN112142843B (fr) |
| AU (1) | AU2014369999B2 (fr) |
| BR (1) | BR112016014810B1 (fr) |
| CA (1) | CA2934644C (fr) |
| DK (1) | DK3087095T3 (fr) |
| EA (1) | EA035324B1 (fr) |
| ES (1) | ES2742682T3 (fr) |
| FI (1) | FIC20230003I1 (fr) |
| FR (1) | FR23C1004I2 (fr) |
| HU (2) | HUE046822T2 (fr) |
| IL (1) | IL246223B (fr) |
| LT (2) | LT3087095T (fr) |
| LU (1) | LUC00284I2 (fr) |
| MX (1) | MX368804B (fr) |
| NL (1) | NL301203I2 (fr) |
| NO (1) | NO2022049I1 (fr) |
| NZ (1) | NZ722055A (fr) |
| PL (1) | PL3087095T3 (fr) |
| PT (1) | PT3087095T (fr) |
| SG (2) | SG10202009832XA (fr) |
| WO (1) | WO2015100299A1 (fr) |
| ZA (2) | ZA201604464B (fr) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220152546A (ko) | 2013-12-24 | 2022-11-16 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Fcrn 길항제 및 사용방법 |
| HUE056775T2 (hu) * | 2015-03-09 | 2022-03-28 | Argenx Bvba | Eljárás Fc-tartalmú szerek szérum szintjeinek csökkentésére FcRn-antagonisták alkalmazásával |
| FR3038517B1 (fr) * | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
| CN106957365B (zh) * | 2016-01-11 | 2021-03-16 | 上海交通大学 | 一种单克隆抗体FnAb8及其应用 |
| CN106957364B (zh) * | 2016-01-11 | 2021-03-16 | 上海交通大学 | 一种单克隆抗体FnAb12及其应用 |
| EP3257866A1 (fr) * | 2016-06-17 | 2017-12-20 | Academisch Medisch Centrum | Anticorps anti-tnf modifiés et leur utilisation dans le traitement de la maladie intestinale inflammatoire |
| CA3030099A1 (fr) | 2016-07-08 | 2018-01-11 | Staten Biotechnology B.V. | Anticorps anti-apoc3 et leurs methodes d'utilisation |
| GB201618424D0 (en) * | 2016-11-01 | 2016-12-14 | Argenix Bvba | Treatment of antibody mediated disease |
| JP7295799B2 (ja) * | 2016-12-02 | 2023-06-21 | ザ テキサス エー アンド エム ユニバーシティー システム | 抗原特異的抗体を選択的に枯渇させるための融合タンパク質 |
| JP2020517242A (ja) | 2017-04-21 | 2020-06-18 | スターテン・バイオテクノロジー・ベー・フェー | 抗ＡｐｏＣ３抗体およびその使用方法 |
| AU2018361957B2 (en) | 2017-10-31 | 2023-05-25 | Staten Biotechnology B.V. | Anti-ApoC3 antibodies and methods of use thereof |
| US10538583B2 (en) | 2017-10-31 | 2020-01-21 | Staten Biotechnology B.V. | Anti-APOC3 antibodies and compositions thereof |
| MX2020005981A (es) * | 2017-12-08 | 2020-08-24 | Argenx Bvba | Uso de antagonistas del fcrn para el tratamiento de la miastenia gravis generalizada. |
| CN112513073A (zh) * | 2018-06-08 | 2021-03-16 | 阿根思公司 | 用于治疗免疫性血小板减少症的组合物和方法 |
| CR20210076A (es) | 2018-07-20 | 2021-09-02 | Momenta Pharmaceuticals Inc | Composiciones de anticuerpo fcrn |
| WO2020054979A1 (fr) * | 2018-09-12 | 2020-03-19 | 아주대학교산학협력단 | Composition comprenant comme principe actif un inhibiteur du cd83, pour la prévention ou le traitement de la maladie de behçet |
| GB2589049C (en) | 2019-04-11 | 2024-02-21 | argenx BV | Anti-IgE antibodies |
| BR112021022682A2 (pt) | 2019-05-14 | 2022-02-22 | Provention Bio Inc | Métodos e composições para prevenir diabetes do tipo 1 |
| JP7565951B2 (ja) | 2019-06-07 | 2024-10-11 | アルジェニクス ビーブイ | 皮下投与に好適なＦｃＲｎインヒビターの医薬製剤 |
| US12403175B2 (en) | 2020-01-08 | 2025-09-02 | argenx BV | Methods for treating pemphigus disorders |
| CN114341184B (zh) * | 2020-02-10 | 2023-04-04 | 北京拓界生物医药科技有限公司 | 抗FcRn抗体、其抗原结合片段及其医药用途 |
| CN113769058B (zh) * | 2020-06-10 | 2024-09-06 | 上海宝济药业股份有限公司 | 一种药物组合及其应用 |
| CA3182445A1 (fr) | 2020-06-11 | 2021-12-16 | Francisco Leon | Procedes et compositions de prevention du diabete de type 1 |
| EP4359432A2 (fr) | 2021-06-23 | 2024-05-01 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Peptides mimétiques d'apoc-ii courts et méthodes d'utilisation |
| KR20240133711A (ko) | 2022-01-18 | 2024-09-04 | 아르제넥스 비브이 | 갈랙틴-10 항체 |
| JP2025508766A (ja) | 2022-02-21 | 2025-04-10 | アルジェニクス ビーブイ | Ｆｃｒｎアンタゴニストを使用して筋炎を治療するための方法 |
| JP2025512483A (ja) | 2022-04-13 | 2025-04-17 | オーエスイー・イミュノセラピューティクス | 抗体を選択的に排除するための分子の新規のクラス |
| IL316418A (en) | 2022-05-05 | 2024-12-01 | Us Health | Short apolipoprotein E mimetic peptides and methods of use |
| WO2023242372A1 (fr) | 2022-06-15 | 2023-12-21 | argenx BV | Molécules de liaison fcrn/hsa et méthodes d'utilisation |
| CN115645537A (zh) * | 2022-10-25 | 2023-01-31 | 成都臻拓医药科技有限公司 | FcRn抑制剂在制备抑制自身免疫性疾病复发的药物中的用途 |
| WO2024105445A2 (fr) * | 2022-11-14 | 2024-05-23 | argenx BV | Molécules antagonistes de fcrn et leurs procédés d'utilisation |
| WO2024163894A1 (fr) | 2023-02-04 | 2024-08-08 | Momenta Pharmaceuticals, Inc. | Compositions et méthodes de traitement d'une maladie hémolytique du fœtus et du nouveau-né |
| KR20250151445A (ko) | 2023-02-17 | 2025-10-21 | 아블린쓰 엔.브이. | 신생아 fc 수용체에 결합하는 폴리펩티드 |
| WO2024206214A1 (fr) * | 2023-03-24 | 2024-10-03 | Paragon Therapeutics, Inc. | Fragments fc qui se lient à fcrn et procédés d'utilisation |
| AR133188A1 (es) | 2023-07-05 | 2025-09-03 | Ablynx Nv | ANTAGONISTAS DE FcRn MEJORADOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON IgG |
| AU2024292990A1 (en) | 2023-07-16 | 2026-01-29 | argenx BV | Methods for treating chronic inflammatory demyelinating polyneuropathy |
| TW202527982A (zh) | 2023-09-11 | 2025-07-16 | 美商默門塔醫藥公司 | Fcrn抗體之醫藥組成物 |
| WO2025099576A1 (fr) | 2023-11-06 | 2025-05-15 | Momenta Pharmaceuticals, Inc. | Compositions et méthodes de traitement de la polyarthrite rhumatoïde |
| GB202319605D0 (en) | 2023-12-20 | 2024-01-31 | argenx BV | Monovalent binding molecules and methods of use |
| WO2025163617A1 (fr) | 2024-02-04 | 2025-08-07 | Momenta Pharmaceuticals, Inc. | Compositions et méthodes de traitement du syndrome de sjögren |
| WO2025186787A1 (fr) | 2024-03-08 | 2025-09-12 | Momenta Pharmaceuticals, Inc. | Compositions et méthodes de traitement de la thrombocytopénie allo-immune fœtale et néonatale |
| WO2025229206A1 (fr) | 2024-05-03 | 2025-11-06 | argenx BV | Molécules de liaison monovalentes anti-iga et procédés d'utilisation |
| WO2025233685A1 (fr) | 2024-05-10 | 2025-11-13 | argenx BV | Formulations d'antagonistes de fcrn intraveineux et leurs procédés d'utilisation |
| WO2025233684A1 (fr) | 2024-05-10 | 2025-11-13 | argenx BV | Formulations sous-cutanées, seringues pré-remplies et leurs procédés d'utilisation |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62153300A (ja) * | 1985-12-26 | 1987-07-08 | Teijin Ltd | ヒト免疫グロブリンＧＦｃ領域蛋白質およびその製造方法 |
| WO1988007089A1 (fr) | 1987-03-18 | 1988-09-22 | Medical Research Council | Anticorps alteres |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5326856A (en) | 1992-04-09 | 1994-07-05 | Cytogen Corporation | Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding |
| AU4116793A (en) | 1992-04-24 | 1993-11-29 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| CA2163345A1 (fr) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Anticorps |
| US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| JP4026848B2 (ja) | 1995-01-17 | 2007-12-26 | ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド | 免疫原の受容体特異的経上皮輸送 |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| CA2249195A1 (fr) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Domaines analogues a l'immunoglobuline a demi-vies prolongees |
| US6128119A (en) | 1997-01-10 | 2000-10-03 | Asahi Kogaku Kogyo Kabushiki Kaisha | Beam shaping optical system |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP1141024B1 (fr) | 1999-01-15 | 2018-08-08 | Genentech, Inc. | POLYPEPTIDE COMPRENANT UNE VARIANTE DE LA REGION Fc DE L'IgG1 HUMAIN |
| DE60122286T2 (de) | 2000-02-11 | 2007-08-02 | Merck Patent Gmbh | Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen |
| US6725230B2 (en) | 2000-07-18 | 2004-04-20 | Aegis Analytical Corporation | System, method and computer program for assembling process data of multi-database origins using a hierarchical display |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| WO2002043658A2 (fr) | 2000-11-06 | 2002-06-06 | The Jackson Laboratory | Traitement a base de fcrn pour troubles autoimmuns |
| ATE540694T1 (de) | 2000-11-20 | 2012-01-15 | Canadian Blood Services | Verfahren zur behandlung der thrombozytopenie mit monoklonalem ivig |
| EP1355919B1 (fr) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules a demi-vies longues, compositions et utilisations de celles-ci |
| EP1423510A4 (fr) | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | Variants de glycosylation d'anticorps presentant une cytotoxicite cellulaire accrue dependante des anticorps |
| US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| JP3945281B2 (ja) | 2002-03-19 | 2007-07-18 | 富士ゼロックス株式会社 | 画像形成装置 |
| DE60334453D1 (de) | 2002-05-30 | 2010-11-18 | Macrogenics Inc | Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten |
| ES2381617T5 (es) | 2002-08-14 | 2016-02-24 | Macrogenics, Inc. | Anticuerpos específicos frente a FcgammaRIIB y sus procedimientos de uso |
| WO2004029207A2 (fr) | 2002-09-27 | 2004-04-08 | Xencor Inc. | Variants fc optimises et methodes destinees a leur generation |
| ATE480562T1 (de) | 2002-10-15 | 2010-09-15 | Facet Biotech Corp | Veränderung von fcrn-bindungsaffinitäten oder von serumhalbwertszeiten von antikörpern mittels mutagenese |
| US7112439B2 (en) | 2003-01-09 | 2006-09-26 | Macrogenics, Inc. | Dual expression vector system for antibody expression in bacterial and mammalian cells |
| AU2004204494B2 (en) | 2003-01-09 | 2011-09-29 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| JP2007525149A (ja) | 2003-01-13 | 2007-09-06 | マクロジェニクス，インコーポレーテッド | 可溶性ＦｃγＲ融合タンパク質およびその使用法 |
| US7662928B2 (en) | 2003-08-08 | 2010-02-16 | The Research Foundation Of State University Of New York | Anti-FcRn antibodies for treatment of auto/allo immune conditions |
| GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
| JP4281800B2 (ja) | 2004-09-30 | 2009-06-17 | ブラザー工業株式会社 | 無線タグ通信装置、無線タグ、無線通信システム、及び無線通信方法 |
| CA2606378A1 (fr) * | 2005-04-29 | 2006-11-09 | The Jackson Laboratory | Anticorops de fcrn et utilisations |
| US8163881B2 (en) * | 2005-05-31 | 2012-04-24 | The Board Of Regents Of The University Of Texas System | Immunoglobulin molecules with improved characteristics |
| TW200745163A (en) | 2006-02-17 | 2007-12-16 | Syntonix Pharmaceuticals Inc | Peptides that block the binding of IgG to FcRn |
| WO2008131242A1 (fr) | 2007-04-18 | 2008-10-30 | Zymogenetics, Inc. | Fc à chaîne simple, procédés de fabrication et procédés de traitement |
| CA2687117A1 (fr) | 2007-05-14 | 2008-11-27 | Biogen Idec Ma Inc. | Regions fc simple chaine, polypeptides de liaison comportant de telles regions, et procedes correspondants |
| EP2641913B1 (fr) * | 2007-06-01 | 2018-04-18 | University of Maryland, Baltimore | Agents de liaison de récepteur Fc de région constante d'immunoglobuline |
| WO2009070748A1 (fr) | 2007-11-27 | 2009-06-04 | Umber Systems | Système pour collecter et analyser des données relatives à une activité de niveau application sur un réseau de données mobile |
| US9260525B2 (en) * | 2008-02-04 | 2016-02-16 | Xiao-Jia Chang | Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof |
| US20110059091A1 (en) * | 2008-02-04 | 2011-03-10 | Xiao-Jia Chang | Inhibitors of oncogenic isoforms and uses thereof |
| US8273351B2 (en) * | 2008-04-25 | 2012-09-25 | Dyax Corp. | Fc receptor binding proteins |
| US20100048488A1 (en) | 2008-08-01 | 2010-02-25 | Syntonix Pharmaceuticals, Inc. | Immunomodulatory peptides |
| EP2233500A1 (fr) * | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Variantes Fc optimisées |
| PL2486141T3 (pl) | 2009-10-07 | 2018-07-31 | Macrogenics, Inc. | Polipeptydy zawierające regiony fc i mające w wyniku zmian w zakresie fukozylacji ulepszoną funkcję efektorową, i sposoby zastosowania tych polipeptydów |
| MX347343B (es) * | 2010-07-28 | 2017-04-21 | Gliknik Inc | Proteinas de fusion de fragmentos de proteinas humanas naturales para crear composiciones de fc de inmunoglobulinas multimerizadas ordenadamente. |
| GB201111291D0 (en) | 2011-06-30 | 2011-08-17 | Agco Int Gmbh | Engine control system |
| CA2853637C (fr) | 2011-10-26 | 2023-04-04 | Novartis Ag | Anticorps monoclonaux cd20 anticanins et methodes d'utilisation |
| WO2013074598A1 (fr) * | 2011-11-18 | 2013-05-23 | Merck Sharp & Dohme Corp. | Polypeptides contenant fc ayant des propriétés anti-inflammatoires améliorées et une liaison améliorée à fcrn |
| KR102041412B1 (ko) * | 2011-12-30 | 2019-11-11 | 한미사이언스 주식회사 | 면역글로불린 Ｆｃ 단편 유도체 |
| GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
| CA3188124A1 (fr) | 2012-07-05 | 2014-01-09 | Genentech, Inc. | Systeme d'expression et de secretion |
| GB201302878D0 (en) | 2013-02-19 | 2013-04-03 | Argen X Bv | Modified igG molecules |
| KR101815265B1 (ko) | 2013-06-20 | 2018-01-04 | 한올바이오파마주식회사 | FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물 |
| EP3663763B1 (fr) | 2013-11-26 | 2022-02-16 | The Brigham and Women's Hospital, Inc. | Compositions et procédés de modulation d'une réponse immunitaire |
| KR20220152546A (ko) | 2013-12-24 | 2022-11-16 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Fcrn 길항제 및 사용방법 |
| MX375080B (es) | 2014-09-17 | 2025-03-06 | Affibody Ab | Polipeptidos novedosos. |
| SMT202300365T1 (it) | 2015-01-30 | 2023-11-13 | Momenta Pharmaceuticals Inc | Anticorpi fcrn e loro metodi di utilizzo |
| HUE056775T2 (hu) | 2015-03-09 | 2022-03-28 | Argenx Bvba | Eljárás Fc-tartalmú szerek szérum szintjeinek csökkentésére FcRn-antagonisták alkalmazásával |
| AU2016262100B2 (en) | 2015-05-12 | 2021-10-14 | Syntimmune, Inc. | Humanized affinity matured anti-FcRn antibodies |
| GB201508180D0 (en) | 2015-05-13 | 2015-06-24 | Ucb Biopharma Sprl | Antibodies |
| EP3325004A1 (fr) | 2015-07-17 | 2018-05-30 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Méthodes et compositions pharmaceutiques pour induire une tolérance immunitaire par vaccination par voie muqueuse avec des antigènes couplés à fc |
| CN106957365B (zh) | 2016-01-11 | 2021-03-16 | 上海交通大学 | 一种单克隆抗体FnAb8及其应用 |
| GB201618424D0 (en) | 2016-11-01 | 2016-12-14 | Argenix Bvba | Treatment of antibody mediated disease |
| MX2020005981A (es) | 2017-12-08 | 2020-08-24 | Argenx Bvba | Uso de antagonistas del fcrn para el tratamiento de la miastenia gravis generalizada. |
| CN112513073A (zh) | 2018-06-08 | 2021-03-16 | 阿根思公司 | 用于治疗免疫性血小板减少症的组合物和方法 |
| JP2022532229A (ja) | 2019-05-17 | 2022-07-13 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 天疱瘡及び類天疱瘡疾患の治療における抗ＦｃＲｎ抗体の使用 |
| JP7565951B2 (ja) * | 2019-06-07 | 2024-10-11 | アルジェニクス ビーブイ | 皮下投与に好適なＦｃＲｎインヒビターの医薬製剤 |
-
2014
- 2014-12-23 KR KR1020227034365A patent/KR20220152546A/ko not_active Ceased
- 2014-12-23 SG SG10202009832XA patent/SG10202009832XA/en unknown
- 2014-12-23 MX MX2016008399A patent/MX368804B/es active IP Right Grant
- 2014-12-23 JP JP2016542697A patent/JP6554473B2/ja active Active
- 2014-12-23 CA CA2934644A patent/CA2934644C/fr active Active
- 2014-12-23 LT LTEP14827372.5T patent/LT3087095T/lt unknown
- 2014-12-23 WO PCT/US2014/072087 patent/WO2015100299A1/fr not_active Ceased
- 2014-12-23 US US14/580,771 patent/US10316073B2/en active Active
- 2014-12-23 KR KR1020247006088A patent/KR20240033084A/ko not_active Ceased
- 2014-12-23 PT PT148273725T patent/PT3087095T/pt unknown
- 2014-12-23 EP EP14827372.5A patent/EP3087095B1/fr active Active
- 2014-12-23 CN CN202010983097.8A patent/CN112142843B/zh active Active
- 2014-12-23 SG SG11201605203UA patent/SG11201605203UA/en unknown
- 2014-12-23 PL PL14827372T patent/PL3087095T3/pl unknown
- 2014-12-23 KR KR1020167020339A patent/KR102452173B1/ko active Active
- 2014-12-23 EP EP19189186.0A patent/EP3626738A1/fr active Pending
- 2014-12-23 AU AU2014369999A patent/AU2014369999B2/en active Active
- 2014-12-23 ES ES14827372T patent/ES2742682T3/es active Active
- 2014-12-23 CN CN201480070435.1A patent/CN106103476B/zh active Active
- 2014-12-23 DK DK14827372T patent/DK3087095T3/da active
- 2014-12-23 NZ NZ722055A patent/NZ722055A/en unknown
- 2014-12-23 HU HUE14827372A patent/HUE046822T2/hu unknown
- 2014-12-23 EA EA201691304A patent/EA035324B1/ru unknown
- 2014-12-23 BR BR112016014810-0A patent/BR112016014810B1/pt active IP Right Grant
-
2016
- 2016-06-14 IL IL246223A patent/IL246223B/en unknown
- 2016-06-30 ZA ZA2016/04464A patent/ZA201604464B/en unknown
-
2017
- 2017-11-22 US US15/821,104 patent/US11505585B2/en active Active
-
2019
- 2019-01-10 JP JP2019002272A patent/JP2019076103A/ja active Pending
-
2022
- 2022-02-15 US US17/672,346 patent/US20220275035A1/en active Pending
- 2022-11-03 NL NL301203C patent/NL301203I2/nl unknown
- 2022-11-09 LU LU00284C patent/LUC00284I2/fr unknown
- 2022-11-15 LT LTPA2022014C patent/LTC3087095I2/lt unknown
- 2022-11-21 HU HUS2200048C patent/HUS2200048I1/hu unknown
- 2022-11-23 NO NO2022049C patent/NO2022049I1/no unknown
-
2023
- 2023-01-12 FR FR23C1004C patent/FR23C1004I2/fr active Active
- 2023-01-19 FI FIC20230003C patent/FIC20230003I1/fi unknown
-
2024
- 2024-12-23 ZA ZA2024/09972A patent/ZA202409972B/en unknown